(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092127 A1

(51) International Patent Classification[7]: C07D 207/16, A61K 31/401, A61P 3/10

(21) International Application Number: PCT/EP2004/003980

(22) International Filing Date: 15 April 2004 (15.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0308854.9 16 April 2003 (16.04.2003) GB
0311836.1 22 May 2003 (22.05.2003) GB

(71) Applicant *(for all designated States except AT, US)*: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SCHÄFER, Frank [DE/DE]; Sennmattstrasse 8, 79618 Rheinfelden-Adelhausen (DE). SEDELMEIER, Gottfried [DE/DE]; Erlenweg 11, 79227 Schallstadt (DE).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/092127 A1

(54) Title: PROCESS FOR THE PREPARATION OF N-SUBSTITUTED 2-CYANOPYRROLIDINES



(V)

(57) Abstract: The present invention relates to a process for the preparation of a N-(N'-substituted glycyl)-2-cyanopyrrolidine comprising at least (a) reacting, in the presence of dimethylformamide, a compound of formula (V) wherein, independently of each other, X_1 and X_3 are halogen; X_2 is halogen, OH, O-C(=O)-CH_2X_3, -O-SO_2-(C_{1-8})alkyl or -O-SO_2-(aryl), with L-prolinamide, followed by (b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by (c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and (d) recovering the resultant cornpound in free form or in acid addition salt form.

PROCESS FOR THE PREPARATION OF N-SUBSTITUTED 2-CYANOPYRROLIDINES

The present invention relates to a novel process for the preparation of N-(N'-substituted glycyl)-2-cyanopyrrolidines and a composition obtainable according to the novel process comprising predominantly N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine.

N-(N'-substituted glycyl)-2-cyanopyrrolidines, especially those of formula I



(I)

wherein R is as defined below; in free form or in acid addition salt form;
are valuable dipeptidyl peptidase-IV (DPP-IV) inhibitors which have been described in WO 98/19998, for example.

The conventional process for preparation of N-(N'-substituted glycyl)-2-cyanopyrrolidines, especially those of formula I above, comprises reacting a halogen (preferably chlorine or bromine) substituted (2-cyanopyrrolidino)carbonylmethylene with an appropriate amine. Said substituted (2-cyanopyrrolidino)carbonylmethylene may be obtained by reacting a haloacetylhalide with L-prolinamide followed by a dehydration with trifluoroacetic anhydride. This process has significant drawbacks, especially when considering industrial production of N-(N'-substituted glycyl)-2-cyanopyrrolidines, as both the 1-haloacetyl-2-cyanopyrrolidine intermediate and its direct precursor are classified as irritant. Furthermore the process needs aqueous work up at several steps resulting in potential waste problems and lower yields. It has also recently been reported an alternative synthesis based on solid phase chemistry which avoids free 1-haloacetyl-2-cyanopyrrolidine but which process is not suitable for scale-up according to its authors (N. Willand et al., Tetrahedron 58 (2002) 5741-5746). Thus, there exists a need for an improved process.

It has now been found that surprisingly the 1-haloacetyl-2-cyanopyrrolidine intermediate may be prepared in such a way that no isolation of said irritant compound is needed. Said compound may therefore be directly further reacted with the appropriate amine. In addition,

the new process allows to recycle all solvents and the only by-products are inorganic salts. The new process is characterised by a high overall yield and is suitable for industrial production.

Therefore, an object of the instant invention is the process for the preparation of a N-(N'-substituted glycyl)-2-cyanopyrrolidine comprising at least
(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



(V)

wherein, independently of each other, X_1 and X_3 are halogen; X_2 is halogen, OH, O-C(=O)-CH_2X_3, -O-SO_2-(C_{1-8})alkyl or -O-SO_2-(aryl),
with L-prolinamide, followed by
(b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by
(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and
(d) recovering the resultant compound in free form or in acid addition salt form.

When X_2 is -O-SO_2-(aryl), the term "aryl" refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6-12 carbon atoms in the ring portion, such as phenyl, biphenyl, naphthyl and tetrahydronaphthyl, each of which may optionally be substituted by 1-4 substituents, such as optionally substituted (C_{1-4})alkyl e.g. trifluoromethyl, halo, hydroxy, (C_{1-4})alkoxy, acyl. Preferably the aryl group is a phenyl, or a substituted phenyl.

When X_2 is -O-SO_2-(C_{1-8})alkyl or -O-SO_2-(aryl), the term "alkyl" refers to either straight or branched chain, which may optionally be substituted by 1-5 substituents selected from halogen preferably fluorine, chlorine, bromine or iodine. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, *n*-butyl, *t*-butyl, isobutyl, trifluoromethyl.

In the above described process, the amine is either a primary or a secondary amine. Such kind of amines useful in organic chemistry, for the synthesis of pharmaceutical compounds

are well known by the person skilled in the art. An appropriate amine substituted by one or two organic groups, can be easily selected by the person skilled in the art based on e.g. the structure of the published DPP-IV inhibitors such as in WO 03/002596.

Specifically, an object of the instant invention is the process for the preparation of a compound of formula (I)



(I)

wherein R is

a) $R_1R_{1a}N(CH_2)_m$ - wherein

R_1 is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen;

R_{1a} is hydrogen or (C_{1-8})alkyl; and

m is 2 or 3;

b) (C_{3-12})cycloalkyl optionally monosubstituted in the 1-position with (C_{1-3})hydroxyalkyl;

c) $R_2(CH_2)_n$ - wherein either

R_2 is phenyl optionally mono- or independently di- or independently trisubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is (C_{1-8})alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C_{1-8})alkyl; a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen; cyclohexenyl; or optionally substituted adamantyl; and

n is 1 to 3; or

R_2 is phenoxy optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen; and

n is 2 or 3;

d) $(R_3)_2CH(CH_2)_2$ - wherein each R_3 independently is phenyl optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen;

e) $R_4(CH_2)_p$ - wherein R_4 is 2-oxopyrrolidinyl or (C_{2-4})alkoxy and p is 2 to 4;

f) isopropyl optionally monosubstituted in 1-position with (C_{1-3})hydroxyalkyl; or

g) R_5 wherein R_5 is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or pluri-substituted with (C_{1-8})alkyl; adamantyl; substituted adamantly; or (C_{1-8})alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono-or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen;

in free form or in acid addition salt form

comprising

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



(V)

wherein, independently of each other, X_1 and X_3 are halogen; X_2 is halogen, OH, O-C(=O)-CH_2X_3, -O-SO_2-(C_{1-8})alkyl or -O-SO_2-(aryl),

with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with a dehydration agent, preferably optionally followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine, preferably a compound of formula (VI)

H_2NR (VI)

wherein R is as defined for formula (I) and

(d) recovering the resultant compound in free form or in acid addition salt form.

Reaction (a) is conveniently carried out under an inert atmosphere and in the presence of dimethylformamide and a further inert, organic solvent or a mixture of such solvents, preferably isopropyl acetate or ethyl acetate. The temperature preferably is from about 5° to about 45°C and most preferred from about 10° to about 35°C. Preferably a 2 to 20% molar excess of (V) is used. Preferably, no base is added. Preferred are compounds of formula (V) wherein both X_1 and X_2 are halogen, preferably chlorine or bromine, particularly preferred X_1 and X_2 are the same and most preferred X_1 and X_2 are both chlorine.

Reaction (b) is conveniently carried out under an inert atmosphere and in the presence of an inert, organic solvent, preferably a mixture of isopropyl acetate and dimethylformamide. The

temperature preferably is from about 15° to about 45°C and most preferred from about 20° to about 35°C. Suitable dehydration agents are (haloalkylene)dialkylammonium halogenids, wherein the alkyl or alkylene is a, preferably straight, carbon chain of 1 to 4 carbon atoms, most preferred methyl or methylene, and halogen is chloro, bromo or iodo, most preferred chloro. Most preferred as a dehydration agent is the Vilsmeier reagent i.e. chloromethylene)dimethylammonium chloride. Preferably a 2 to 20% molar excess of the dehydration agent is used. Subsequently any excess of Vilsmeier reagent may be decomposed by the addition of a small amount of water.

Reaction (c) is conveniently carried out under an inert atmosphere whereby the resultant reaction product of (b) is added to a solution or suspension of the amine compound of formula (VI) in an inert, organic solvent, preferably 2-butanone, aceton, acetonitrile or dimethylformamide The temperature preferably is from about 5° to about 60°C and most preferred from about 10° to about 35°C. Preferably a catalytic amount (for example 1 to 10%, preferably about 5%) of potassium iodide is used. The amine of formula (VI) is used in 5 to 35% molar excess, preferably in 10 to 25% molar excess. Conveniently the base, used in an amount of 2 to 10 eq, preferably about 5.5 eq, may be an alkali carbonate or NaOH, preferably Na_2CO_3 or K_2CO_3 and most preferred K_2CO_3.

Recovery (d) conveniently comprises filtering the reaction mixture, removing the solvents under reduced pressure and recrystallising the crude product from a solvent containing an organic or inorganic base. In a preferred embodiment, the solvent contains a N-base, for example 1,8-diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine, $N(C_4H_9)_3$, $N(C_2H_5)_3$, isobutylmorpholine or tetramethylpiperidine.

The compounds of formula (I) can exist in "free form" or in acid addition salt form. Salt forms may be recovered from the "free form" in known manner and vice versa. Acid addition salts may e.g. be those of pharmaceutically acceptable organic or inorganic acids. Although the preferred acid addition salts are the hydrochlorides, salts of methanesulfonic, sulfuric, phosphoric, citric, lactic and acetic acid may also be utilized.

"Alkyl" and "alkoxy" are either straight or branched chain, of which examples of the latter are isopropyl and tert-butyl.

R preferably is a) or c) as defined above.

R_1 preferably is a pyridinyl or pyrimidinyl or piperazinyl moiety optionally substituted as defined above. R_{1a} preferably is hydrogen. R_2 preferably is optionally substituted phenyl or adamantyl. R_3 preferably is unsubstituted phenyl. R_4 preferably is alkoxy as defined above. R_5 preferably is optionally substituted alkyl as defined above, m preferably is 2. n preferably is 1 or 2, especially 2. p preferably is 2 or 3, especially 3.

Pyridinyl preferably is pyridin-2-yl; it preferably is unsubstituted or monosubstituted, preferably in 5-position. Pyrimidinyl preferably is pyrimidin-2-yl. It preferably is unsubstituted or monosubstituted, preferably in 4-position. Preferred as substitutents for pyridinyl and pyrimidinyl are halogen, cyano and nitro, especially cyano.
When it is substituted, phenyl preferably is monosubstituted; it preferably is substituted with halogen, preferably chlorine, or methoxy. It preferably is substituted in 2-, 4- and/or 5-position, especially in 4-position.
(C_{3-12})cycloalkyl preferably is cyclopentyl or cyclohexyl. When it is substituted, it preferably is substituted with hydroxymethyl. (C_{2-4})alkoxy preferably is of 1 or 2 carbon atoms, it especially is methoxy. (C_{1-8})alkoxy preferably is of 3 carbon atoms, it especially is isopropoxy. Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, especially chlorine. (C_{1-8})alkyl preferably is of 1 to 6, preferably 1 to 4 or 3 to 5, especially of 2 or 3 carbon atoms, or methyl. (C_{1-4}) alkyl preferably is methyl or ethyl, especially methyl. (C_{1-3})hydroxyalkyl preferably is hydroxymethyl.
A [3.1.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[3.1.1]hept-2-yl optionally disubstituted in 6-position with methyl, or bicyclo[3.1.1]hept-3-yl optionally trisubstituted with one methyl in 2-position and two methyl groups in 6-position. A [2.2.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[2.2.1]hept-2-yl.
Naphthyl preferably is 1-naphthyl. Cyclohexene preferably is cyclohex-1-en-l-yl. Adamantyl preferably is unsubstituted or substituted by one or more, for example 2 substituents 1- or 2-adamantyl. Preferred substituents are selected from alkyl, $-OR_{10}$ or $-NR_{11}R_{12}$; where R_{10}, R_{11} and R_{12} are independently hydrogen, alkyl, C_{1-8}alkanoyl, carbamyl, or $-CONR_{13}R_{14}$; where R_{13} and R_{14} are independently alkyl, unsubstituted or substituted aryl and where one of R_{13} and R_{14} additionally is hydrogen or R_{13} and R_{14} together represent C_{2-7}alkylene.

A pyrrolidinyl or piperidinyl moiety optionally substituted as defined above preferably is pyrrolidin-3-yl or piperidin-4-yl. When it is substituted it preferably is N-substituted.

Very preferred are compounds of formula (I)
wherein

R is $R_2(CH_2)_n$- and R_2 is substituted adamantyl; and

n is 0, 1, 2 or 3; in free form or in acid addition salt form;

A preferred group is one of above compounds of formula (I) wherein the substituent on the adamantyl is bonded on a bridgehead.

Especially preferred compounds are compounds of formula



(IA)

or



(IB)

wherein R' is hydroxy, C_{1-7}alkoxy, C_{1-8}alkanoyloxy, or R'''R''''N-C(O)O-, where R''' and R'''' independently are C_{1-7}alkyl or phenyl which is unsubstituted or substituted by a substituent selected from C_{1-7}alkyl, C_{1-7}alkoxy, halogen and trifluormethyl and where R''' additionally is hydrogen; or R''' and R'''' together are C_{3-6}alkylene; and R'' is hydrogen; or R' and R'' independently are C_{1-7}alkyl; in free form or in acid addition salt form.

Very particularly preferred is the compound of formula (IA) wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form. This compound is also known as pyrrolidine, 1-[(3-hydroxy-1-adamantyl) amino] acetyl-2-cyano-, (S) or LAF237.

The preferred appropriate amine, is a compound of formula (VI)

H_2NR (VI)

wherein the preferred R are the same as those defined for formula (I), especially R is $R_2(CH_2)_n$- and R_2 is substituted adamantly especially as defined above; and

n is 0, 1, 2 or 3; in free form or in acid addition salt form;

The compounds of formula (I) exist in the form of optically active isomers or stereoisomers and can be separated and recovered by conventional techniques, however the above described process is capable of yielding compounds of formula (I) with a high (at least 95%) enantiomeric purity of the N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine.

Therefore, a further object of the instant invention is a composition of N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, obtainable according to the above described process, whereby 95% to 99,9% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 5% to 0,1% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, especially whereby 98% to 99,9% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 2% to 0,1% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine and preferably whereby 98% to 99,99% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 2% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, and very preferably whereby 99% to 99,99% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 1% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine.

In a further embodiment the present invention covers a composition e.g. a pharmaceutical composition comprising a N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and a N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, whereby 95% to 99,9% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 5% to 0,1% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, preferably whereby 95% to 99,99% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 5% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, most preferably whereby 98% to 99,99% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 2% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine and very preferably whereby 99% to 99,99% is N-

(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 1% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine. A preferred example is a composition e.g. a pharmaceutical composition of N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, whereby 99% to 99,5% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 1% to 0,5% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, or whereby 99,2% to 99,9% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 0.8% to 0,1% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine

A further object of the instant invention is a composition of N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and/or N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, obtainable according to the above described process.

Preferably, the instant invention is a composition comprising N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and/or N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, wherein the only by-products are inorganic salts, preferably obtainable according to the above described process.

The present invention also concerns;

i) a pharmaceutical composition comprising,

a) one or more pharmaceutically acceptable excipients, and

b) at least one N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine obtainable according to the above described process.

ii) a pharmaceutical composition comprising,

a) one or more pharmaceutically acceptable excipients, and

b) at least one N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine, and

c) between 0.00001% and 5% by weight of at least one (haloalkylene)dialkylammonium halogenid preferably chloromethylene)dimethylammonium chloride.

Preferably the N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine is obtainable according to the above described process

Preferred N-(N'-substituted glycyl)-2(S)-cyanopyrrolidines are those described as preferred compounds in the above process.

Examples

Example 1)

Preparation of Pyrrolidine, 1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-, (S):

Step (a)

A 1500 ml reactor, equipped with a mechanical stirrer, is charged with 212 g isopropyl-acetate and 19.8 g dimethylformamide. The reactor is inertized. At about IT (internal temperature) 15 °C, 125 g chloroacetylchloride is added within 15 min., after complete addition the IT is adjusted to about 15 °C, and a solution of 110 g L-prolinamide in 304 g dimethylformamide is added within 1 h. The addition funnel is rinsed with 18 g isopropyl-acetate. The reaction mixture is warmed to about IT 35 °C for 1.5 h.

Step (b)

After cooling to about 15 °C 142 g Vilsmeier reagent is added in portions. The reaction mixture is stirred for 1 h at about IT 25 °C. At IT max. 25 °C 4.4 g water is added.

Step (c)

A 4.5 l reactor, equipped with a mechanical stirrer, is charged with 733 g of potassium carbonate, 194 g 3-hydroxyaminoadamantane, 8.0 g potassium iodide and 880 g 2-butanone. The suspension is heated to about 35 °C. At this temperature 937 g solution of step b) (crude (S)-1-chloroacetyl-pyrrolidine-2-carbonitrile) is added within 1.5 h. The addition funnel is rinsed with 20 g 2-butanone. After stirring for an additional 1 h, the suspension is warmed to about IT 70 °C for 30 min. The warm suspension is filtered and the filter cake is rinsed three times with warm 331 g 2-butanone. The filtrate is concentrated at about JT (jacket temperature) 60 °C under reduced pressure (about 20 mbar).

Step (d)

At about JT 60 °C 8.8 g 1,8-diazabicyclo[5.4.0]undec-7-ene and 44 g isopropanol is added and stirred for 30 min. at IT about 60 °C. The resulting suspension is cooled to about IT 40 °C and at JT 40 °C 814 g t-butylmethylether is added. The suspension is cooled to about IT 20 °C and stirred for at least 2 h at this temperature, then cooled to about –10°C - 0 °C, stirred for 1 h and filtered. The filtration "cake" is washed twice with 168 g of a cold (about -10 °C)

1:1 (v:v) mixture of isopropanol and t-butylmethylether. The crude product (247 g) is dried under reduced pressure at about JT 55 °C.

Example 2:
Purification of Pyrrolidine, 1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-, (S):

A 750 ml reactor, equipped with a mechanical stirrer, is charged with 199 g of crude 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile), 800 g 2-butanone. The mixture is heated to reflux (JT 95 °C) and stirred for 15 min. The mixture is filtered into a warm (JT 75 °C) reactor, the filter cake is washed with 80 g 2-butanone. The IT is adjusted to 70 °C and 0.18 g (1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile) suspended in 1.6 g 2-butanone are added. The resulting suspension is stirred for 30 min., cooled to IT 50 °C within 2 h then to 30 °C within 1 h finally to 0 °C within 1 h and stirred for 1 additional h. After this the suspension is filtered and the crude product is washed twice with a cold (0°C) mixture of 60.4 g 2-butanone and 55.5 g t-butyl methyl ether. The product is dried under reduced pressure at about JT 55 °C. The melting point is 148°C.

Claims:

1. Process for the preparation of a N-(N'-substituted glycyl)-2-cyanopyrrolidine comprising at least

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



(V)

wherein, independently of each other, X_1 and X_3 are halogen; X_2 is halogen, OH, O-C(=O)-CH_2X_3, -O-SO_2-(C_{1-8})alkyl or -O-SO_2-(aryl),

with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and

(d) recovering the resultant compound in free form or in acid addition salt form.

2. A process according to claim 1 wherein the N-(N'-substituted glycyl)-2-cyanopyrrolidine is a compound of formula (I)



(I)

wherein R is

a) $R_1R_{1a}N(CH_2)_m$ - wherein

R_1 is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen;

R_{1a} is hydrogen or (C_{1-8})alkyl; and

m is 2 or 3;

b) (C_{3-12})cycloalkyl optionally monosubstituted in the 1-position with (C_{1-3})hydroxyalkyl;

c) $R_2(CH_2)_n$ - wherein either

R_2 is phenyl optionally mono- or independently di- or independently trisubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is (C_{1-8})alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C_{1-8})alkyl; a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen; cyclohexenyl; or optionally substituted adamantyl; and

n is 1 to 3; or

R_2 is phenoxy optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen; and

n is 2 or 3;

d) $(R_3)_2CH(CH_2)_2$- wherein each R_3 independently is phenyl optionally mono- or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen;

e) $R_4(CH_2)_p$ - wherein R_4 is 2-oxopyrrolidinyl or (C_{2-4})alkoxy and p is 2 to 4;

f) isopropyl optionally monosubstituted in 1-position with (C_{1-3})hydroxyalkyl; or

g) R_5 wherein R_5 is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or multi-substituted with (C_{1-8})alkyl; adamantyl; substituted adamantyl ;or (C_{1-8})alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono-or independently disubstituted with (C_{1-4})alkyl, (C_{1-4})alkoxy or halogen;

in free form or in acid addition salt form.

3. A process according to claim 1 or 2 wherein the dehydration agent of step (b) is a (haloalkylene)dialkylammonium halogenid.

4. A process according to claim 1 or 2 wherein the dehydration agent of step (b) is (chloromethylene)dimethylammonium chloride.

5. A process according to claim 2 wherein the amine of step (c) is a compound of formula (VI)

H_2NR (VI)

wherein R is as defined for formula (I) in claim 2.

6. A process according to claim 2 comprising

(a) reacting, in the presence of dimethylformamide, a compound of formula (V)



(V)

wherein X_1 is halogen; X_2 is halogen, OH, O-C(=O)-CH_2X, -O-SO_2-(C_{1-8})alkyl or -O-SO_2-(aryl), with L-prolinamide, followed by

(b) reacting the resultant compound without isolation with (chloromethylene)dimethylammonium chloride, followed by

(c) reacting, in the presence of a base, the resultant compound without isolation with a compound of formula (VI)

H_2NR (VI)

wherein R is as defined for formula (I) and

(d) recovering the resultant compound in free form or in acid addition salt form.

7. A process according to claim 6 wherein R is $R_2(CH_2)_n$- and R_2 is substituted adamantyl; and n is 0, 1, 2 or 3.

8. A composition of N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, obtainable according to the process of claim 1 or 2, whereby 95% to 99,9% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 5% to 0,1% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, especially whereby 98% to 99,99% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 2% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine.

9. A composition comprising a N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and a N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, whereby 98% to 99,9% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 2% to 0,1% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, preferably whereby 98% to 99,99% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 2% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, most preferably whereby 99% to 99,99% is N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and 1% to 0,01% is N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine.

10. A composition of N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine and N-(N'-substituted glycyl)-2(R)-cyanopyrrolidine, obtainable according to the process of claim 1 or 2.

11. A pharmaceutical composition comprising,

a) one or more pharmaceutically acceptable excipients, and

b) at least one N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine obtainable according to the process of claim 1 or 2.

12. A pharmaceutical composition comprising,

a) one or more pharmaceutically acceptable excipients, and

b) at least one N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine, and

c) between 0.00001% and 5% by weight of at least one (haloalkylene)dialkylammonium halogenid.

13. A composition according to claim 12, wherein the N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine is obtainable according to the process of claim 1 or 2.

14. A composition according to any of claim 8 to 13, whereby the N-(N'-substituted glycyl)-2(S)-cyanopyrrolidine is a compound of the formula



(IA)

wherein R' is hydroxy and R'' is hydrogen in free form or in acid addition salt form.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/003980

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D207/16 A61K31/401 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/19998 A (CIBA GEIGY AG ; VILLHAUER EDWIN BERNARD (US)) 14 May 1998 (1998-05-14) cited in the application examples	1-14
Y	WO 00/34241 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); VILLHAUER EDWIN BERNA) 15 June 2000 (2000-06-15) page 10; example 1B	1-14
Y	WO 01/96295 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); VILLHAUER EDWIN BERNA) 20 December 2001 (2001-12-20) page 11; example 1A	1-14

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
9 September 2004	20/09/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Menegaki, F

Form PCT/ISA/210 (second sheet) (January 2004)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 380 398 B2 (KANSTRUP ANDERS ET AL) 30 April 2002 (2002-04-30) column 13, line 30	1-14
A	NICOLAS WILLAND, ET AL: "Solid and solution phase syntheses of the 2-cyanopyrrolidide DPP-IV inhibitor NVP-DPP728" TETRAHEDRON, vol. 58, 2002, pages 5741-5746, XP002295278 UK cited in the application page 5741 - page 5742	1-14

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9819998 A	14-05-1998	AT 271543 T	15-08-2004
		AU 726186 B2	02-11-2000
		AU 5318498 A	29-05-1998
		BR 9714130 A	29-02-2000
		CA 2269810 A1	14-05-1998
		CN 1236361 A ,B	24-11-1999
		CZ 9901615 A3	11-08-1999
		DE 69729947 D1	26-08-2004
		WO 9819998 A2	14-05-1998
		EP 0937040 A2	25-08-1999
		HU 0000323 A2	28-08-2000
		ID 18331 A	26-03-1998
		ID 21350 A	27-05-1999
		JP 3217380 B2	09-10-2001
		JP 2000511559 T	05-09-2000
		KR 2000053081 A	25-08-2000
		NO 992028 A	28-04-1999
		NZ 335146 A	29-11-1999
		PL 332777 A1	11-10-1999
		RU 2180901 C2	27-03-2002
		SK 60899 A3	10-04-2000
		TR 9901004 T2	21-07-1999
		TW 492957 B	01-07-2002
		ZA 9709985 A	07-05-1998
WO 0034241 A	15-06-2000	AU 759773 B2	01-05-2003
		AU 1658000 A	26-06-2000
		BR 9915985 A	04-09-2001
		CA 2350609 A1	15-06-2000
		CN 1329593 T	02-01-2002
		CZ 20012028 A3	12-09-2001
		WO 0034241 A1	15-06-2000
		EP 1137635 A1	04-10-2001
		HU 0104495 A2	29-04-2002
		ID 28796 A	05-07-2001
		JP 2002531547 T	24-09-2002
		NO 20012853 A	07-08-2001
		NZ 511935 A	28-11-2003
		PL 348043 A1	06-05-2002
		SK 7892001 A3	06-11-2001
		TR 200101478 T2	22-10-2001
		TW 509674 B	11-11-2002
		US 6166063 A	26-12-2000
		ZA 200104581 A	22-05-2002
WO 0196295 A	20-12-2001	AU 1359702 A	24-12-2001
		CA 2411778 A1	20-12-2001
		WO 0196295 A2	20-12-2001
		EP 1296974 A2	02-04-2003
		JP 2004503531 T	05-02-2004
US 6380398 B2	18-10-2001	US 2001031780 A1	18-10-2001
		US 2002103384 A1	01-08-2002
		AU 2830901 A	07-08-2001
		WO 0155105 A1	02-08-2001
		EP 1254113 A1	06-11-2002
		JP 2003520849 T	08-07-2003
		AU 3362201 A	03-09-2001

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/003980

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6380398 B2		WO 0162266 A2	30-08-2001
		EP 1259246 A2	27-11-2002
		JP 2003523396 T	05-08-2003
		US 2001025023 A1	27-09-2001